Screening
Screening in the general population is impractical. The World Health Organization does recommend screening in countries where prevalence is >3% to 5% in males. In the US, screening of high-risk ethnic groups such as the Kurdish Jews, in whom the prevalence of G6PD is 50%-70%, may be worthwhile.[6]
Use of this content is subject to our disclaimer